Eli Lilly and Company [NYSE: LLY] stock went on a downward path that fall over -1.41% on Monday, amounting to a one-week price decrease of less than -5.15%. Over the last 12 months, LLY stock rose by 26.65%. The one-year Eli Lilly and Company stock forecast points to a potential upside of 9.28. The average equity rating for LLY stock is currently 2.40, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $135.87 billion, with 908.20 million shares outstanding and 792.56 million shares in the current float. Compared to the average trading volume of 4.31M shares, LLY stock reached a trading volume of 3706172 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Guru’s Opinion on Eli Lilly and Company [LLY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LLY shares is $156.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LLY stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Eli Lilly and Company shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on April 21, 2020. The new note on the price target was released on April 09, 2020, representing the official price target for Eli Lilly and Company stock. On December 18, 2019, analysts increased their price target for LLY shares from 116 to 150.
The Average True Range (ATR) for Eli Lilly and Company is set at 4.21, with the Price to Sales ratio for LLY stock in the period of the last 12 months amounting to 5.88. The Price to Book ratio for the last quarter was 41.75, with the Price to Cash per share for the same quarter was set at 1.85. Price to Free Cash Flow for LLY in the course of the last twelve months was 98.79 with Quick ratio for the last quarter at 0.90.
LLY Stock Performance Analysis:
Eli Lilly and Company [LLY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.15. With this latest performance, LLY shares dropped by -10.65% in over the last four-week period, additionally plugging by 16.29% over the last 6 months – not to mention a rise of 26.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LLY stock in for the last two-week period is set at 32.40, with the RSI for the last a single of trading hit 26.13, and the three-weeks RSI is set at 39.70 for Eli Lilly and Company [LLY]. The present Moving Average for the last 50 days of trading for this stock 152.35, while it was recorded at 145.85 for the last single week of trading, and 131.55 for the last 200 days.
Insight into Eli Lilly and Company Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Eli Lilly and Company [LLY] shares currently have an operating margin of +25.94 and a Gross Margin at +78.85. Eli Lilly and Company’s Net Margin is presently recorded at +20.78.
Return on Total Capital for LLY is now 27.37, given the latest momentum, and Return on Invested Capital for the company is 24.17. Return on Equity for this stock inclined to 74.59, with Return on Assets sitting at 11.15. When it comes to the capital structure of this company, Eli Lilly and Company [LLY] has a Total Debt to Total Equity ratio set at 610.90. Additionally, LLY Total Debt to Total Capital is recorded at 85.93, with Total Debt to Total Assets ending up at 40.54. Long-Term Debt to Equity for the company is recorded at 548.72, with the Long-Term Debt to Total Capital now at 77.19.
Reflecting on the efficiency of the workforce at the company, Eli Lilly and Company [LLY] managed to generate an average of $137,930 per employee. Receivables Turnover for the company is 3.80 with a Total Asset Turnover recorded at a value of 0.54.Eli Lilly and Company’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.90 and a Current Ratio set at 1.10.
LLY Stock EPS
With the latest financial reports released by the company, Eli Lilly and Company posted 1.5/share EPS, while the average EPS was predicted by analysts to be reported at 1.45/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for LLY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Eli Lilly and Company go to 12.24%.
Eli Lilly and Company [LLY] Insider Position Details
There are presently around $107,872 million, or 79.70% of LLY stock, in the hands of institutional investors. The top three institutional holders of LLY stocks are: LILLY ENDOWMENT INC with ownership of 113,271,342, which is approximately -1.125% of the company’s market cap and around 11.80% of the total institutional ownership; VANGUARD GROUP INC, holding 72,675,648 shares of the stock with an approximate value of $10.43 billion in LLY stocks shares; and BLACKROCK INC., currently with $9.23 billion in LLY stock with ownership of nearly 5.618% of the company’s market capitalization.
Positions in Eli Lilly and Company stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 686 institutional holders increased their position in Eli Lilly and Company [NYSE:LLY] by around 51,181,358 shares. Additionally, 770 investors decreased positions by around 46,925,415 shares, while 330 investors held positions by with 653,406,334 shares. The mentioned changes placed institutional holdings at 751,513,107 shares, according to the latest SEC report filing. LLY stock had 127 new institutional investments in for a total of 3,789,757 shares, while 91 institutional investors sold positions of 2,159,985 shares during the same period.